Page 16 - Xlife Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate announcements from Xlife Sciences AG, Breakthrough in Drug Development

First available holistic medical drug to treat Covid-19 and flu viruses ZURICH, SWITZERLAND - EQS Newswire - 10 June 2021 - As a project company of Xlife Sciences AG (XLS DE), inflamed pharma GmbH has developed a revolutionary and holistic therapeutic approach to treat both SARS-CoV-2 and flu viruses. The patented active substance ProcCluster (R) reduces the viral load by...

DGAP-News: Xlife Sciences AG: Portfolio project listed on the Stock Exchange Xlife Sciences AG: Portfolio project listed on the Stock Exchange 14.05.2021 / 15:41 PRESS RELEASE Vitruvia Medical AG is listed on the Munich Stock Exchange since yesterday The shares of Vitruvia Medical AG are open for trading since yesterday on the Stock exchange in Munich. Vitruvia is based in Germany and Switzerland and develops circulatory systems for highly complex medical devices as a project portfolio of Xlife Sciences AG (XLS). The initial offering price of the shares is at EUR 22.60, above expectations....

Operator Welcome to the Q1 2021 Athenex, Inc. Earnings Conference Call. My name is Richard, and I'll be your operator for today's call. [Operator Instructions] I am now going to call over Mr. Steven Rubis, Senior Director, Investor Relations. Steven, you may begin. Steven Rubis -- Investor Relations Good morning, and thank you for joining our conference call. Today, we will provide an update on Athenex's business as well as a review of financial results for the first quarter of 2021. The news release detailing the results crossed the wire earlier this morning and is available on the company'...

DGAP-News: Xlife Sciences AG / Key word(s): Merger 05.03.2021 / 07:30 Xlife Sciences AG (XLS): Joint venture with anfass Life Technologies Development of highly effective antibodies without animal testing Xlife Sciences AG and Solothurn-based anfass Life Technologies AG have entered a joint venture. Hence, the jointly founded Quadira Biosciences AG has access to the 3D CoSeedis(TM) technology platform of abc biopply ag. This unique 3D cell technology enables the replication of human tissue for reliable testing and characterization of antibodies without animal testing. Xlife's technology pla...